Rezolute (RZLT) Non-Current Assets (2012 - 2026)
Rezolute (RZLT) posted Non-Current Assets of $3.4 million for Q1 2026, down 3.21% sequentially from $3.5 million in Q4 2025, and down 43.2% YoY from $6.0 million in Q1 2025.
Rezolute (RZLT) Non-Current Assets (2012 - 2026) Analysis & Trends
Rezolute has reported Non-Current Assets for 15 years, with the latest figure at $3.4 million in Q1 2026.
- Quarterly Non-Current Assets fell 43.2% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.2 million (down 58.42% YoY) and the FY2025 annual result came in at $4.3 million, up 6.39% from the prior year.
- Non-Current Assets declined to $3.4 million in Q1 2026 per RZLT's latest filing, from $3.5 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $28.7 million in Q1 2023 and troughed at $316000.0 in Q2 2022.
- A 5-year average of $7.6 million and a median of $5.2 million in 2022 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets soared 5852.85% in 2023, then sank 80.73% in 2024.
- Over 5 years, Non-Current Assets stood at $2.6 million in 2022, then jumped by 133.09% to $6.1 million in 2023, then surged by 119.51% to $13.3 million in 2024, then plunged by 73.54% to $3.5 million in 2025, then slipped by 3.21% to $3.4 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $3.4 million, $3.5 million, and $4.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Rezolute | 442.94 Mn | 442.94 Mn | - | 3.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.41 Mn |
| Dec 31, 2025 | 3.52 Mn |
| Sep 30, 2025 | 3.96 Mn |
| Jun 30, 2025 | 4.35 Mn |
| Mar 31, 2025 | 6.00 Mn |
| Dec 31, 2024 | 13.31 Mn |
| Sep 30, 2024 | 13.24 Mn |
| Jun 30, 2024 | 4.08 Mn |
| Mar 31, 2024 | 5.53 Mn |
| Dec 31, 2023 | 6.07 Mn |
| Sep 30, 2023 | 10.35 Mn |
| Jun 30, 2023 | 18.81 Mn |
| Mar 31, 2023 | 28.68 Mn |
| Dec 31, 2022 | 2.60 Mn |
| Sep 30, 2022 | 361,000.00 |
| Jun 30, 2022 | 316,000.00 |
| Mar 31, 2022 | 5.24 Mn |
| Dec 31, 2021 | 5.31 Mn |
| Sep 30, 2021 | 415,000.00 |
| Jun 30, 2021 | 616,000.00 |